Compare GWH & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWH | NNVC |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 21.2M |
| IPO Year | N/A | 2008 |
| Metric | GWH | NNVC |
|---|---|---|
| Price | $0.86 | $1.57 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.25 | N/A |
| AVG Volume (30 Days) | ★ 625.2K | 365.1K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.99 | N/A |
| Revenue Next Year | $1,328.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $0.85 |
| 52 Week High | $13.87 | $2.23 |
| Indicator | GWH | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 38.07 | 60.06 |
| Support Level | N/A | $1.35 |
| Resistance Level | $1.22 | $2.23 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 29.92 | 55.88 |
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. It develops and manufactures long-duration energy storage systems based on iron flow battery technology. The company's batteries use earth-abundant materials, including iron, salt, and water, and are designed for high cycle life and recyclability. It operates as a single business operating segment, which includes all activities related to the design, engineering, and manufacturing of the company's long duration energy storage products. The company's revenue is derived from the sale of its energy storage products and from service contracts.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.